Insights from the ISPOR Panel on the European Health Data Space

By João L. Carapinha

November 13, 2023

The European Health Data Space (EHDS) represents a groundbreaking initiative by the European Commission, poised to advance healthcare data management across the EU. As discussed in the recent ISPOR Europe conference panel, the EHDS is much more than a tool for pharmacovigilance and retrospective cohort studies.

It’s a comprehensive framework designed to empower EU citizens with equitable access to healthcare data while ensuring data privacy and fostering participation in intellectual property creation.

The EHDS is set to enhance the digitalization of health records and propel research. It supports the efficient utilization of electronic healthcare records and deployment of artificial intelligence for data analysis.

This advancement is not only expected to deepen research capabilities but also to spur innovation and improve policy-making at all societal levels.

Key opportunities presented by the EHDS include increased access to data and the attractiveness of Europe as a hub for clinical research, ultimately translating into improved patient outcomes. However, the implementation of the EHDS is not without challenges. These include ensuring transparency and trust in data sharing, addressing patient willingness to opt into data sharing, and navigating data protection and privacy concerns.

A significant challenge lies in extending the scope of EHDS beyond existing laws and regulations, aiming to build a stronger health data network backed by EU member states’ support.

Furthermore, panelists highlighted the importance of evaluating the readiness of EU member states to participate in the EHDS. Cultural barriers were identified as a critical hurdle, as the EHDS requires substantial organizational changes to facilitate the sharing, storage, and availability of data to various users and the research community.

As the EHDS progresses, it will undergo continuous improvement, driven by feedback from users and researchers accessing the data. This initiative is not just a standalone project but an integral component of the broader European Union. It aligns with the European strategy for data, indicating a holistic approach to data management and utilization across various sectors in the EU, with health data being a priority area.

In summary, the European Health Data Space is an ambitious and transformative project. It holds the promise of reshaping the landscape of healthcare research, policy-making, and industry practices within the EU, setting a precedent for the rest of the world in healthcare data management and utilization.

Reference url

Recent Posts

biosimilars price competition
      

The Impact of MFN Pricing on the U.S. Biosimilar Market

💊 Could MFN Pricing Undermine Biosimilars?

MFN drug pricing aims to cut costs—but its indirect pressure on biosimilars may reduce competition (create a void) and raise long-term prices.

Explore the risks and what stakeholders can do to protect market sustainability.

#SyenzaNews #Biosimilars #DrugPricing #HealthPolicy #Pharma #MarketAccess

EU AI Act Healthcare Compliance
     

Navigating EU AI Act Healthcare Compliance: Proactive Steps for Ethical AI Integration

🔍 Are you prepared for the upcoming EU AI Act in healthcare?

As the first comprehensive AI regulation globally rolls out, healthcare organizations must move beyond mere compliance. The urgency lies in embedding ethical, trusted, and sustainable AI practices into every facet of healthcare AI. Early adoption of ethical assessments and collaboration is essential to navigate the complex regulatory landscape before the August 2026 deadline.

Learn about proactive compliance strategies that not only meet regulatory standards but also enhance patient trust and system efficacy!

#SyenzaNews #AIinHealthcare #HealthcareInnovation #DigitalTransformation

hepatitis vaccine uptake
         

Hepatitis Vaccine Uptake: Trends, Challenges, and the Role of Pharmacists

💉 Are we doing enough to bridge the gap in hepatitis vaccine uptake?

A recent article highlights that while over 90% of children are vaccinated against hepatitis B, adult rates are alarmingly low, posing a significant public health risk. Jeff Goad from the National Foundation for Infectious Diseases emphasizes the crucial role pharmacists can play in increasing access and dispelling common misconceptions about vaccines.

Join the conversation on enhancing vaccination strategies for better health outcomes!

#SyenzaNews #Healthcare #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.